WYE-354 is primarily used in biochemical and pharmacological research as a potent and selective inhibitor of mTOR (mammalian target of rapamycin), a key protein kinase involved in cell growth, proliferation, and survival. It is widely applied in studies targeting the PI3K/AKT/mTOR signaling pathway, which is often dysregulated in cancers and other diseases. Due to its ability to inhibit both mTORC1 and mTORC2 complexes, WYE-354 provides a more comprehensive suppression of mTOR signaling compared to traditional inhibitors like rapamycin, making it valuable in cancer research, particularly in evaluating tumor growth suppression and resistance mechanisms. It is also used in studies related to autophagy, metabolism, and aging, where mTOR activity plays a central regulatory role. Because of its cell permeability and specificity, WYE-354 serves as a useful tool compound in cellular assays and preclinical models to dissect mTOR-dependent processes and assess potential therapeutic strategies for diseases involving hyperactive mTOR signaling.